Microsatellite instability : Review of methods and applications

After introduction of the Bethesda microsatellite test panel demonstration of microsatellite instability (MSI) and/or loss of mismatch repair proteins (MMRD) was primarily used as a marker for cancer predisposition of Lynch syndrome (LS, previous: HNPCC). Nowadays MSI/MMRD has become an important bi...

Full description

Saved in:
Bibliographic Details
Published in:Der Pathologe 2019-05, Vol.40 (3), p.313-327
Main Authors: Dietmaier, W, Büttner, R, Rüschoff, J
Format: Article
Language:ger
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:After introduction of the Bethesda microsatellite test panel demonstration of microsatellite instability (MSI) and/or loss of mismatch repair proteins (MMRD) was primarily used as a marker for cancer predisposition of Lynch syndrome (LS, previous: HNPCC). Nowadays MSI/MMRD has become an important biomarker to predict therapy response to checkpoint immunotherapies. MSI can be determined either by polymerase chain reaction (PCR)-based technologies with or without specification of fragment sizes or next generation sequencing (NGS) methods. Depending on the individual tumor entities, these test methods are used differently. Currently, MSI/MMRD is a tumor biomarker which covers a broad spectrum of indications in tumor pathology, especially in colorectal, endometrial and gastric cancer. In advanced carcinomas, MSI is an established predictor of therapy response to checkpoint-directed immunotherapies.
ISSN:1432-1963
DOI:10.1007/s00292-019-0610-7